EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Plasma S100A12 Levels and Peripheral Arterial Disease in End-Stage Renal Disease

Yayoi Shiotsu, Yasukiyo Mori, Tsuguru Hatta, Noboru Maki, Kumiko Iida, Eiko Matsuoka, Hiroshi Kado, Ryo Ishida, Noriko Kishimoto, Keiichi Tamagaki, Masato Nishimura, Noriyuki Iwamoto und 3 weitere

Nephron Extra · 21.12.2011 · 1 (1) · 242-250

DOI: 10.1159/000335198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephron Extra, online erschienen am 21.12.2011. Verfasst von Yayoi Shiotsu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Nephrology, Kyoto Prefectural University of Medicine, Kyoto. Die Arbeit wurde bisher 14-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

S100A12 is an endogenous ligand of the receptor for advanced glycation end products (RAGE). Plasma S100A12 levels are high in end-stage renal disease (ESRD) patients undergoing maintenance hemodialysis (HD). Peripheral arterial disease (PAD) is common in HD patients and is associated with increased cardiovascular morbidity and mortality rates in this population. To date, however, no study has specifically assessed the relationship between plasma S100A12 and PAD in HD patients.

Methods

We conducted a cross-sectional study of 152 HD patients in our affiliated hospital. We investigated PAD history and patient characteristics and quantified plasma S100A12 levels in all participants.

Results

HD patients with PAD (n = 26; 21.9 [13.6–33.4] ng/ml) showed significantly higher plasma S100A12 levels than HD patients without PAD (n = 126; 11.8 [7.5–17.6]ng/ml; p < 0.001). In multivariate logistic regression analysis, the plasma S100A12 level (odds ratio [OR] 5.71; 95% confidence interval [CI] 1.29–25.3; p = 0.022) was identified as an independent factor associated with PAD prevalence. Another factor associated with PAD prevalence was the ankle-brachial index (OR 0.54; 95% CI 0.40–0.74; p < 0.001).

Conclusion

These results suggest that plasma S100A12 levels are strongly associated with PAD prevalence in ESRD patients undergoing HD.

Schlagwörter

Stichwörter der Autor:innen

Chronic kidney diseasePeripheral arterial diseaseReceptor for advanced glycation end productsS100A12

Autor:innen und Institutionen

  • Department of Cardiology and Nephrology, Kyoto Prefectural University of Medicine, Kyoto.

Zitieren

APA

Shiotsu, Y., Mori, Y., Hatta, T., Maki, N., Iida, K., Matsuoka, E., Kado, H., Ishida, R., Kishimoto, N., Tamagaki, K., Nishimura, M., Iwamoto, N., Ono, T., Matsubara, H., & Kosaki, A. (2011). Plasma S100A12 Levels and Peripheral Arterial Disease in End-Stage Renal Disease. Nephron Extra, 1(1), 242-250. https://doi.org/10.1159/000335198

Vancouver

Shiotsu Y, Mori Y, Hatta T, Maki N, Iida K, Matsuoka E, et al. Plasma S100A12 Levels and Peripheral Arterial Disease in End-Stage Renal Disease. Nephron Extra. 2011;1(1):242-250. doi:10.1159/000335198

BibTeX
@article{Shiotsu2011,
  author = {Shiotsu, Yayoi and Mori, Yasukiyo and Hatta, Tsuguru and Maki, Noboru and Iida, Kumiko and Matsuoka, Eiko and Kado, Hiroshi and Ishida, Ryo and Kishimoto, Noriko and Tamagaki, Keiichi and Nishimura, Masato and Iwamoto, Noriyuki and Ono, Toshihiko and Matsubara, Hiroaki and Kosaki, Atsushi},
  title = {Plasma S100A12 Levels and Peripheral Arterial Disease in End-Stage Renal Disease},
  journal = {Nephron Extra},
  year = {2011},
  volume = {1},
  number = {1},
  pages = {242--250},
  doi = {10.1159/000335198}
}
Kostenlos starten →